Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications

Murtuza Bharmal, Krista Payne, Mark J Atkinson, Marie-Pierre Desrosiers, Donald E Morisky, Eric Gemmen, Murtuza Bharmal, Krista Payne, Mark J Atkinson, Marie-Pierre Desrosiers, Donald E Morisky, Eric Gemmen

Abstract

Background: The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales--side effects, effectiveness, convenience and global satisfaction. In naturalistic studies, administering the TSQM with the side effects domain could provoke the physician to assess the presence or absence of adverse events in a way that is clinically atypical, carrying the potential to interfere with routine medical care. As a result, an abbreviated 9-item TSQM (TSQM-9), derived from the TSQM Version 1.4 but without the five items of the side effects domain was created. In this study, an interactive voice response system (IVRS)-administered TSQM-9 was psychometrically evaluated among patients taking antihypertensive medication.

Methods: A total of 3,387 subjects were invited to participate in the study from an online panel who self-reported taking a prescribed antihypertensive medication. The subjects were asked to complete the IVRS-administered TSQM-9 at the start of the study, along with the modified Morisky scale, and again within 7 to 14 days. Standard psychometric analyses were conducted; including Cronbach's alpha, intraclass correlation coefficients, structural equation modeling, Spearman correlation coefficients and analysis of covariance (ANCOVA).

Results: A total of 396 subjects completed all the study procedures. Approximately 50% subjects were male with a good racial/ethnic mix: 58.3% white, 18.9% black, 17.7% Hispanic and 5.1% either Asian or other. There was evidence of construct validity of the TSQM-9 based on the structural equation modeling findings of the observed data fitting the Decisional Balance Model of Treatment Satisfaction even without the side effects domain. TSQM-9 domains had high internal consistency as evident from Cronbach's alpha values of 0.84 and greater. TSQM-9 domains also demonstrated good test-retest reliability with high intraclass correlation coefficients exceeding 0.70. As expected, the TSQM-9 domains were able to differentiate between individuals who were low, medium and high compliers of medication, with moderate to high effect sizes. There was evidence of convergent validity with significant correlations with the medication adherence scale.

Conclusion: The IVRS-administered TSQM-9 was found to be a reliable and valid measure to assess treatment satisfaction in naturalistic study designs, in which there is potential that the administration of the side effects domain of the TSQM would interfere with routine clinical care.

Figures

Figure 1
Figure 1
Study Sample.
Figure 2
Figure 2
Structural Equation Modeling Analysis for the TSQM-9.

References

    1. Zhiwei Zhang, Gerstein DR, Friedmann PD. Patient satisfaction and sustained outcomes of drug abuse treatment. J Health Psychol. 2008;13:388–400. doi: 10.1177/1359105307088142.
    1. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189–99.
    1. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811. doi: 10.1097/00005650-200209000-00009.
    1. Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405. doi: 10.2337/dc06-1497.
    1. Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77:219–26. doi: 10.1159/000126073.
    1. Wroth TH, Pathman DE. Primary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with care. J Am Board Fam Med. 2006;19:478–86. doi: 10.3122/jabfm.19.5.478.
    1. Kumar RN, Kirking DM, Hass SL, Vinokur AD, Taylor SD, Atkinson MJ, McKercher PL. The association of consumer expectations, experiences and satisfaction with newly prescribed medications. Qual Life Res. 2007;16:1127–36. doi: 10.1007/s11136-007-9222-4.
    1. Gill KJ. Social psychological artifacts in the measurement of consumer satisfaction with health care. Dissertation Abstracts International: Section B: The Sciences & Engineering. 1996;57:1495.
    1. Chatterton ML, Scott-Lennox J, Wu AW, Vinokur AD, Taylor SD, Atkinson MJ, McKercher PL. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection. PharmacoEcon. 1999;15:67–74. doi: 10.2165/00019053-199915001-00006.
    1. Cohen JA, Beall D, Beck A, Rawlings J, Miller DW, Clements B, Pait DG, Batenhorst A. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clinical Therapeutics. 1999;21:190–204. doi: 10.1016/S0149-2918(00)88278-8.
    1. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clinical Therapeutics. 2001;23:127–145. doi: 10.1016/S0149-2918(01)80036-9.
    1. Lewis R, Bennett CJ, Borkon WD, J Boykin WH, Althof SE, Stecher VJ, Siegel RL. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology. 2001;57:960–965. doi: 10.1016/S0090-4295(01)00945-1.
    1. Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment satisfaction measure for asthmatics: a validation study. Qual Life Res. 2000;9:873–882. doi: 10.1023/A:1008913209828.
    1. Atkinson MJ, Lennox RD. Extending basic principles of measurement models to the design and validation of Patient Reported Outcomes. Health Qual Life Outcomes. 2006;4:65. doi: 10.1186/1477-7525-4-65.
    1. Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. Gut. 2004;53:iv40–4. doi: 10.1136/gut.2003.034322.
    1. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health. 2004;7:204–15. doi: 10.1111/j.1524-4733.2004.72252.x.
    1. Baró E, Casado A, García-Cases C, Clerch L, Ribas S. Assessing satisfaction with pain medication in primary care patients: development and psychometric validation of a new measure. Clin Ther. 2004;26:1124–36. doi: 10.1016/S0149-2918(04)90185-3.
    1. Anderson RT, Girman CJ, Pawaskar MD, Camacho FT, Calles J, Kelly WS, Demuro C, Balkrishnan R. The Diabetes Medication Satisfaction Tool (DMSAT): A Focus on Treatment Regimens. Diabetes Care. 2008.
    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.
    1. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8:S9–S24. doi: 10.1111/j.1524-4733.2005.00066.x.
    1. Carreño M, Gil-Nagel A, Sánchez JC, Elices E, Serratosa JM, Salas-Puig J, Villanueva V, Porcel J. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav. 2008;13:178–83. doi: 10.1016/j.yebeh.2008.02.006.
    1. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2006.
    1. Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension. 2008;10:348–354. doi: 10.1111/j.1751-7176.2008.07572.x.
    1. Hatcher L. A Step-by-Step Approach to Using the SAS System for Factor Analysis and Structural Equation Modeling. SAS Publishing; 1994.
    1. Browne M, Cudeck R. Alternative ways of assessing model fit. Socio Methods Res. 1992;21:230–59. doi: 10.1177/0049124192021002005.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555.
    1. Cohen J. A power primer. Psychological Bulletin. 1992;112:155–159. doi: 10.1037/0033-2909.112.1.155.
    1. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174. doi: 10.2307/2529310.
    1. SAS 9.1 for Windows. SAS Institute, Cary, NC; 2004.
    1. Nunnally J, Bernstein I. Psychometric Theory. 3. New York: McGraw Hill; 1994.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit